111, Inc. Announces First Quarter 2022 Unaudited Financial Results
SHANGHAI, June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Net revenues were RMB2.98 billion (US$470.5 million), representing an...
New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity in Asia
COVID-19 pandemic triggered massive surge in virtual health and care delivery across the world, with regions including Asia embracing hybrid virtual and in-person services Report from the Broadband Commission for Sustainable Development Working Group on Virtual Health and Care – co-chaired by the World Health Organization and the Novartis Foundation – provides learnings from 23 countries Report...
Global Pharmaceutical Market Drives Innovative Digitalization to Accelerate Drug Discovery
According to Frost & Sullivan, digitalization across the pharmaceutical value chain will improve the industry´s efficiency. SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Pharmaceuticals Outlook, finds that the accelerated drug development timelines are driving digitalization and innovation across the pharmaceutical value chain. Data, the decentralization of clinical trials, supply-chain resilience, digital therapeutics, and...
Implantica Applauded by Frost & Sullivan for Transforming Gastroesophageal Reflux Disease Treatment with Its Revolutionary Implant RefluxStop™
The RefluxStop™ device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of proton pump inhibitors (PPIs) and existing surgical methods and devices for treating acid reflux disease. SAN ANTONIO, June 16, 2022 /PRNewswire/ --– Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica...
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead therapeutic candidate, STP705, for the treatment of skin cancer, in the May 2022 issue of the Journal of Drugs in...
GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION
– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV – SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed the health-related quality of life...
Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022
- The updates of ASC22 Phase IIb study will be presented at the oral session during the International Liver Congress™ 2022 on Saturday, June 16, 2022 at 14:15, Beijing Time (Abstract Number: OS091) HANGZHOU, China and SHAOXING, China, June 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the latest results of the Phase IIb...
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies
PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 16, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer...
Novotech and Medidata expand partnership to continue advancements in clinical research
Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew partnership, further expanding services to Novotech clients in APAC and the US SINGAPORE, June 16, 2022 /PRNewswire/ -- Medidata, a Dassault Systèmes company, today announced its renewed, expanded partnership with Novotech, a leading contract research organisation (CRO), to continue scaling clinical studies in...
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
BOSTON and LAUSANNE, Switzerland, June 16, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT). The Company's shareholders...
